These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23863802)

  • 21. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.
    Suh JW; Koo BK; Zhang SY; Park KW; Cho JY; Jang IJ; Lee DS; Sohn DW; Lee MM; Kim HS
    CMAJ; 2006 Jun; 174(12):1715-22. PubMed ID: 16754899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between the CYP3A5 genotype and blood pressure.
    Ho H; Pinto A; Hall SD; Flockhart DA; Li L; Skaar TC; Cadman P; O'Connor DT; Wagner U; Fineberg NS; Weinberger MH
    Hypertension; 2005 Feb; 45(2):294-8. PubMed ID: 15596575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
    Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study.
    Kivistö KT; Niemi M; Schaeffeler E; Pitkälä K; Tilvis R; Fromm MF; Schwab M; Lang F; Eichelbaum M; Strandberg T
    Am J Pharmacogenomics; 2005; 5(3):191-5. PubMed ID: 15952872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
    Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
    Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population.
    Kreutz R; Zuurman M; Kain S; Bolbrinker J; de Jong PE; Navis G
    Pharmacogenet Genomics; 2005 Dec; 15(12):831-7. PubMed ID: 16272955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
    Song HY; Xia JS; Chen YG; Chen L
    Hum Exp Toxicol; 2022; 41():9603271221080236. PubMed ID: 35099304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.
    Rodríguez-Jiménez C; García-Saiz M; Pérez-Tamajón L; Salido E; Torres A
    Drug Metab Pers Ther; 2017 Mar; 32(1):49-58. PubMed ID: 28245187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
    Song HY; Xia JS; Chen YG; Chen L
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S646-S653. PubMed ID: 34784831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele.
    Bolbrinker J; Seeberg S; Schostak M; Kempkensteffen C; Baelde H; de Heer E; Kreutz R
    Drug Metab Dispos; 2012 Apr; 40(4):639-41. PubMed ID: 22214815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tacrolimus Dose Optimization Strategy for Refractory Ulcerative Colitis Based on the Cytochrome P450 3A5 Polymorphism Prediction Using Trough Concentration after 24 Hours.
    Onodera M; Endo K; Naito T; Moroi R; Kuroha M; Kanazawa Y; Kimura T; Shiga H; Kakuta Y; Negoro K; Kinouchi Y; Shimosegawa T
    Digestion; 2018; 97(1):90-96. PubMed ID: 29393157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of CYP3A5 genotypes with blood pressure and renal function in African families.
    Bochud M; Eap CB; Elston RC; Bovet P; Maillard M; Schild L; Shamlaye C; Burnier M
    J Hypertens; 2006 May; 24(5):923-9. PubMed ID: 16612255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.
    Uno T; Wada K; Matsuda S; Terada Y; Oita A; Kawase A; Takada M
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):665-673. PubMed ID: 29691732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
    Suzuki Y; Fujioka T; Sato F; Matsumoto K; Muraya N; Tanaka R; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
    Br J Clin Pharmacol; 2015 Dec; 80(6):1421-8. PubMed ID: 26773964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical significance of cytochrome P450 genetic polymorphism--part IV. Cytochrome P450 3A4 and 3A5].
    Duricová J; Grundmann M
    Ceska Slov Farm; 2011 Dec; 60(6):276-82. PubMed ID: 22312850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.
    Vourvahis M; McFadyen L; Nepal S; Valluri SR; Fang A; Fate GD; Wood LS; Marshall JC; Chan PLS; Nedderman A; Haynes J; Savage ME; Clark A; Smith KY; Heera J
    J Clin Pharmacol; 2019 Jan; 59(1):139-152. PubMed ID: 30192390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.